摘要
自从2002年美国肾脏病基金会(NKF)公布的K/DOQI指南(肾脏病与透析患者生存质量指导指南)中首次提出慢性肾脏病(chronickidneydisease,CKD)的定义以来,在世界范围内引发了对于CKD的广泛关注。CKD现已成为全球性的公共健康问题,它危害的人群之多远远超出了人们的想象,
出处
《中华临床医师杂志(电子版)》
CAS
2013年第17期5-6,共2页
Chinese Journal of Clinicians(Electronic Edition)
参考文献10
-
1孙宁玲.对2007年ESC/ESH高血压指南的理解及评价[J].心血管病学进展,2007,28(5):675-677. 被引量:13
-
2谌贻璞.ACEI与ARB肾脏保护作用研究进展[J].中国医药导刊,2007,9(2):122-124. 被引量:28
-
3贾强.血管紧张素转化酶抑制剂和血管紧张素Ⅱ受体拮抗剂联合应用对肾脏的保护作用[J].中国综合临床,2003,19(8):677-678. 被引量:1
-
4National Kidney Foundation Kidney.K/DOQI clinical practice guidelines for chronic kidney disease:evaluation,classification and stratification[].American Journal of Kidney Diseases.2002
-
5Chobanian AV,Bakris GL,Black HR,et al.The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report[].Journal of the American Medical Association The.2003
-
6Mann Johannes F E,Schmieder Roland E,McQueen Matthew,Dyal Leanne,Schumacher Helmut,Pogue Janice,Wang Xingyu,Maggioni Aldo,Budaj Andrzej,Chaithiraphan Suphachai,Dickstein Kenneth,Keltai Matyas,Mets?rinne Kaj,Oto Ali,Parkhomenko Alexander,Pie.Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial[].The Lancet.2008
-
7Coresh Josef,Selvin Elizabeth,Stevens Lesley A,Manzi Jane,Kusek John W,Eggers Paul,Van Lente Frederick,Levey Andrew S.Prevalence of chronic kidney disease in the United States[].JAMA : the journal of the American Medical Association.2007
-
8Hallan Stein I,Coresh Josef,Astor Brad C,Asberg Arne,Powe Neil R,Romundstad Solfrid,Hallan Hans A,Lydersen Stian,Holmen Jostein.International comparison of the relationship of chronic kidney disease prevalence and ESRD risk[].Journal of the American Society of Nephrology : JASN.2006
-
9Peterson J C,Adler S,Burkart J M,et al.Blood pressure control, proteinuria, and the progression of renal disease.The Modification of Diet in Renal Disease Study[].Annals of Internal Medicine.1995
-
10Fan Fan Hou,Di Xie,Xun Zhang,Ping Yan Chen,Wei Ru Zhang,Min Liang,Zhi Jian Guo,Jian Ping Jiang.Clinical Science Articles - Clinical Nephrology - Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: A Randomized Controlled Study of Benazepril and Losartan in Chronic Renal Insufficiency[].Journal of the American Society of Nephrology : JASN.2007
二级参考文献33
-
1谌贻璞.慢性肾脏病高血压的治疗目标及药物应用[J].临床内科杂志,2005,22(11):726-728. 被引量:26
-
2唐政,宦红娣.血管紧张素Ⅱ与肾脏硬化的研究进展[J].肾脏病与透析肾移植杂志,1996,5(5):43-49. 被引量:11
-
3Gainer JV, Morrow JD, Loveland A, et al. Effect of bradykinin-receptor blockade on the response to angiotensin-converting--enzyme inhibitor in normotensive and hypertensive subjects [ J ]. N Engt J Med,1998,339( 18 ) : 1285-1292.
-
4Fauvel JP,Velon S, Berra N,et al. Effects of losaxtan on renal function in patients with essential hypertention[ J]. J Cardiovasc Pharmacol,1996,28(2) :259-263.
-
5Burdmann EA ,Andoh TF,Nast CC ,et al. Prevention of experimental cyclosporin-induced interstitial fibrosis by losartan and enalapril [ J ].Am J Physiol. 1995.269(4 Pt 2) :491-499.
-
6Russo D, Pisani A, Balletta MM ,et al. Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive with IgA nephropathy[ J]. Am J Kidney Dis,1999,33(5) :851-856.
-
7Tylicki L, Rutkowski P, Renke M, et al. Ranoprotective effect of small doses of losartan and enalapril in patients with primary gtomerulonephritis. Shor-term observation [ J ]. Am J Nephrol, 2002,22(4) :356-362.
-
8Herbert LA,Falkenhain ME,Nahman Jr NS,et al. Combination ACE inhibitor and angiotensin Ⅱ receptor antagonist therapy in diabetic nephropathy[ J ]. Am J Nephrol, 1999,19 ( 1 ) : 1-6.
-
9Carey RM ,Wang ZQ,Siragy HM,et al. Role of angiotensin Ⅱ type 2 receptor in the regulation of blood pressure and renal function[ J].Hypertension,2000,35 ( 1 Pt 2) :155-163.
-
10Oparil S,Weber MA.Hypertension:A Companion to Brenner and Rector's The Kidney.St.Louis:Saunders,2000; 70 ~ 110
共引文献39
-
1朱宇雷.社区干预对于血压正常高值居民血压控制的研究[J].医学信息(医学与计算机应用),2014,0(18):417-417.
-
2傅汉菁.ARB在糖尿病患者中的临床应用[J].药品评价,2008,5(8):350-354. 被引量:8
-
3文青松.血管紧张素转换酶抑制剂致急性肾功能衰竭22例临床分析[J].内科,2008,3(4):556-557.
-
4刘少旋,王埃连,耿立霞.代文联用硝苯地平缓释片治疗原发性高血压疗效分析[J].中国误诊学杂志,2008,8(27):6627-6628. 被引量:6
-
5谭昭.血管紧张素Ⅱ拮抗剂的肾损害[J].中国医药导刊,2008,10(6):821-823.
-
6谌贻璞.慢性肾脏病与肾素-血管紧张素-醛固酮系统及高血压[J].中华内科杂志,2008,47(11):888-890. 被引量:9
-
7赖剑波,江勇,姚志军,李健球.苯那普利对高血压肾病患者尿微量白蛋白和C反应蛋白的影响[J].中华高血压杂志,2009,17(1):76-77. 被引量:3
-
8郑萍,李亦蕾,晏媛.高血压合并脑梗死的药物治疗分析[J].中国医院药学杂志,2009,29(15):1327-1329. 被引量:2
-
9王淑萍.药物的肾保护作用[J].中国现代药物应用,2009,3(19):191-192.
-
10秦方,闫亚非,唐丹,余波,陈春梅,李军,陈新云,伍悦蕾,刘敏,叶小平.成都社区医生高血压防治知识及社区高血压治疗现状[J].四川医学,2010,31(2):150-152. 被引量:6
同被引文献8
-
1陈庆书,杨萍,张伦军,田玲莉.随机尿蛋白定量在蛋白尿检测中的应用价值[J].中华全科医学,2009,7(12):1366-1367. 被引量:4
-
2曹生亚,李佳,杨鸿鹏,李磊.尿蛋白定量与定性比较研究[J].齐齐哈尔医学院学报,2015,36(4):513-514. 被引量:4
-
3李珊珊,解汝娟,包宇实.不同疾病背景下慢性肾脏病的流行趋势及危险因素[J].医学综述,2016,22(17):3394-3398. 被引量:4
-
4郭春花,林冲云.60例无症状性血尿和(或)蛋白尿患者的临床与病理分析研究[J].临床肾脏病杂志,2016,16(9):535-538. 被引量:1
-
5刘飞,毛建华.蛋白尿与慢性肾脏病[J].中国实用儿科杂志,2016,31(11):816-820. 被引量:13
-
6陈灿锋,王家健,侯晓涛,李连青.2型糖尿病肾病病理分型特点与尿蛋白的关系[J].标记免疫分析与临床,2017,24(2):183-188. 被引量:44
-
7王羽,汪裕伟.皖南地区812例慢性肾脏病病理分型及流行病学调查[J].包头医学院学报,2018,34(4):103-106. 被引量:2
-
8姚佳玉,徐燕华,苏惠娟,谭翠莲.尿白蛋白/尿肌酐比值在慢性肾脏病分期筛查中的应用[J].皖南医学院学报,2018,37(2):134-136. 被引量:7
-
1白强.代谢综合征离勃起功能障碍多远[J].大众医学,2015,0(8):58-58.
-
2高峰.骨质疏松离你有多远[J].健康生活,2013(10):17-17. 被引量:1
-
3徐璧云.肾病离尿毒症有多远[J].家庭医药(就医选药),2007(10):42-42.
-
4韩殿冰,陈维佩,郭光金.脾脏对远位器官(组织)的调节作用[J].岭南现代临床外科,2002,2(4):245-246. 被引量:3
-
5林钐,邓跃毅,张先闻.胱抑素C及CGFR评价慢性肾脏病肾功能的临床意义[J].中国中西医结合肾病杂志,2010,11(9):807-809. 被引量:12
-
6赵杨,姜群(指导专家).慢性肾炎离尿毒症有多远[J].健康世界,2009(4):30-31.
-
7张彩群.高危药离我们有多远?[J].名医,2013(4):63-64.
-
8钱卫康.更年期,距离骨质疏松有多远[J].大众医学,2013(8):36-36.
-
9尹学兵.更年期距离骨质疏松有多远[J].自我保健,2013(9):74-74.
-
10张瑞岩.慢性肾病对冠心病发病和预后的影响[J].内科理论与实践,2006,1(2):94-98. 被引量:1